Approaches to advancing quantitative human health risk assessment of environmental chemicals in the post-genomic era

Toxicology and Applied Pharmacology

Volumn 271, Issue 3, 2013, Pages 309-323

  Chiu, Weihsueh A ^a   Euling, Susan Y ^a   Scott, Cheryl Siegel ^a   Subramaniam, Ravi P ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Biomarkers; Dose response assessment; Molecular epidemiology; Risk assessment; Toxicogenomics

Indexed keywords

BIOLOGICAL MARKER; ENVIRONMENTAL CHEMICAL;

ARTICLE; CASE STUDY; CLINICAL PRACTICE; COMPUTER MODEL; ENVIRONMENTAL EXPOSURE; GENOMICS; HEALTH HAZARD; HUMAN; HUMAN GENOME; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR BIOLOGY; MOLECULAR EPIDEMIOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SAFETY; POPULATION RISK; PUBLIC HEALTH; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; TOXICITY; TOXICOLOGY;

AGENCY FOR TOXIC SUBSTANCES AND DISEASE REGISTRY; ATSDR; BENCHMARK DOSE; BIOMARKERS; BMD; DNA-PROTEIN CROSSLINKS; DOSE-RESPONSE ASSESSMENT; DPX; ENVIRONMENTAL PROTECTION AGENCY; EPA; GENE ONTOLOGY; GLUTATHIONE-S-TRANSFERASE; GO; GST; HIGH THROUGHPUT/HIGH CONTENT; HT/HC; HUGE; HUMAN GENOME EPIDEMIOLOGY; INTEGRATE RISK INFORMATION SYSTEM; INTELLIGENCE QUOTIENT; IQ; IRIS; LOAEL; LOWEST OBSERVED ADVERSE EFFECT LEVEL; MOA; MODE OF ACTION; MOLECULAR EPIDEMIOLOGY; NATIONAL CENTER FOR COMPUTATIONAL TOXICOLOGY; NATIONAL RESEARCH COUNCIL; NCCT; NO OBSERVED ADVERSE EFFECT LEVEL; NO OBSERVED TRANSCRIPTIONAL EFFECT LEVEL; NOAEL; NOTEL; NRC; POD; POINT OF DEPARTURE; QRA; QUANTITATIVE RISK ASSESSMENT; REFERENCE CONCENTRATION; REFERENCE DOSE; RFC; RFD; RISK ASSESSMENT; TOXICOGENOMICS;

ANIMALS; BIOLOGICAL MARKERS; ENVIRONMENTAL POLLUTANTS; GENOMICS; HUMANS; RISK ASSESSMENT;

ANIMALIA;

EID: 84883739748     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2010.03.019     Document Type: Article

References (112)

1. Allen D.G., Pearse G., Haseman J.K., Maronpot R.R. Prediction of rodent carcinogenesis: an evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies. Toxicol. Pathol. 2004, 32:393-401.
2. Andersen M.E., Clewell H.J., Bermudez E., et al. Genomic signatures and dose-dependent transitions in nasal epithelial responses to inhaled formaldehyde in the rat. Toxicol. Sci. 2008, 105(2):368-383.
3. Axelrad D.A., Bellinger D.C., Ryan L.M., Woodruff T.J. Dose-response relationship of prenatal mercury exposure and IQ: an integrative analysis of epidemiologic data. Environ. Health Perspect. 2007, 115(4):609-615.
4. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69(3):89-95. Biomarkers Definitions Working Group.
5. Burgoon L.D., Zacharewski T.R. Automated quantitative dose-response modeling and point of departure determination for large toxicogenomic and high-throughput screening data sets. Toxicol. Sci. 2008, 104(2):412-418.
6. Canfield R.L., Henderson C.R., Cory-Slechta D.A., Cox C., Jusko T.A., Lanphear B.P. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl. J. Med. Apr 17 2003, 348(16):1517-1526.
7. Caporaso N.E. Integrative study designs - next step in the evolution of molecular epidemiology?. Cancer Epidemiol. Biomarkers Pre 2007, 16:365-366.
8. Casanova M., Deyo D.F., Heck H.D. Covalent binding of inhaled formaldehyde to DNA in the nasal mucosa of Fischer 344 rats: analysis of formaldehyde and DNA by high-performance liquid chromatography and provisional pharmacokinetic interpretation. Fundam. Appl. Toxicol. 1989, 12(3):397-417.
9. Chang C.H., Hsiao C.F., Chang G.C., Tsai Y.H., Chen Y.M., Huang M.S., Su W.C., Hsieh W.S., Yang P.C., Chen C.J., Hsiung C.A. Interactive effect of cigarette smoking with human 8-oxoguanine DNA N-glycosylase 1 (HOGG1) polymorphisms on the risk of lung cancer: a case-control study in Taiwan. Am. J. Epidemiol. 2009, 170:695-702.
10. Cohen S.M. Risk assessment in the genomic era. Toxicol. Pathol. 2004, 32(Suppl 1):3-8.
11. Collins F.S., Gray G.M., Bucher J.R. Toxicology. Transforming environmental health protection. Science 2008, 319(5865):906-907.
12. Conolly R.B., Kimbell J.S., Janszen D., Schlosser P.M., Kalisak D., Preston J., Miller F.J. Biologically motivated computational modeling of formaldehyde carcinogenicity in the F344 rat. Toxicol. Sci. 2003, 75(2):432-447.
13. Conolly R.B., Kimbell J.S., Janszen D., Schlosser P.M., Kalisak D., Preston J., Miller F.J. Human respiratory tract cancer risks of inhaled formaldehyde: dose-response predictions derived from biologically-motivated computational modeling of a combined rodent and human dataset. Toxicol. Sci. 2004, 82(1):279-296.
14. Conolly R.B. Commentary on "Toxicity testing in the 21st century: implications for human health risk assessment" by Krewski et al. Risk Anal. 2009, 29(4):480-481. discussion 492-7.
15. Conolly R.B., Miller F.J., Kimbell J.S., et al. Formaldehyde risk assessment. Ann. Hyg. 2009, 53:181-184.
16. Crump K.S., Chen C., Fox J.F., et al. Sensitivity analysis of biologically motivated model for formaldehyde-induced respiratory cancer in humans. Ann. Occup. Hyg. 2008, 52:481-495.
17. Crump K.S., Chen C., Fox J.F., et al. Reply to Conolly et al. (2009). Ann. Occup. Hyg. 2009, 53:184-189.
18. Crump K.S., Chen C., Chiu W.A., Louis T.A., Portier C.J., Subramaniam R.P., White P.D. What role for biologically-based dose-response models in estimating low-dose risk?. Environ. Health Perspect. 2010, Epub 2010. 4 Jan. doi:10.1289/ehp.0901249. (available at http://dx.doi.org/).
19. Daston G.P. Gene expression, dose-response, and phenotypic anchoring: applications for toxicogenomics in risk assessment. Toxicol. Sci. 2008, 105(2):233-234. Epub 2008 Aug 6.
20. David R.M., Clewell H.J., Gentry P.R., Covington T.R., Morgott D.A., Marino D.J. Revised assessment of cancer risk to dichloromethane II. Application of probabilistic methods to cancer risk determinations. Regul. Toxicol. Pharmacol. 2006, 45(1):55-65.
21. Dix D.J., Gallagher K., Benson W.H., Groskinsky B.L., McClintock J.T., Dearfield K.L., Farland W.H. A framework for the use of genomics data at the EPA. Nat. Biotechnol. 2006, 24(9):1108-1111.
22. Dix D.J., Houck K.A., Martin M.T., Richard A.M., Setzer R.W., Kavlock R.J. The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol. Sci. 2007, 95(1):5-12.
23. Dourson M.L., Stara J.F. Regulatory history and experimental support of uncertainty (safety) factors. Regul. Toxicol. Pharmacol. 1983, 3:224-238.
24. El-Masri H.A., Bell D.A., Portier C.J. Effects of glutathione transferase theta polymorphism on the risk estimates of dichloromethane to humans. Toxicol. Appl. Pharmacol. 1999, 158(3):221-230.
25. Euling, S.Y., Makris, S., White, L., Chiu, W., Benson, R., Thompson, C., Keshava, N., Keshava, C., Ovacik, A.M., Sen, B., Gaido, K., Androulakis, I.P., Hester, S., Wilson, V., Gray Jr., L.E., Foster, P., Kim, A.S., 2010-this issue. An approach to using toxicogenomic data in risk assessment: the dibutyl phthalate case study. Toxicology and Applied Pharmacology Toxicogenomics in Risk Assessment Special Issue. Volume, Issue, Page Numbers TBD.
26. Evans J.S., Rhomberg L.R., Williams P.L., Wilson A.M., Baird S.J. Reproductive and developmental risks from ethylene oxide: a probabilistic characterization of possible regulatory thresholds. Risk Anal. 2001, 21(4):697-717.
27. Feero W.G., Guttmacher A.E., Collins F.S. The genome gets personal - almost. JAMA 2008, 299(11):1351-1352.
28. Gant T.W. Novel and future applications of microarrays in toxicological research. Expert Opin. Drug Metab. Toxicol. 2007, 3(4):599-608.
29. Gaylor D.W., Kodell R.L. Percentiles of the product of uncertainty factors for establishing probabilistic risk doses. Risk Anal. 2000, 20:245-250.
30. Georgopoulos P.G., Sasso A.F., Isukapalli S.S., Lioy P.J., Vallero D.A., Okino M., Reiter L. Reconstructing population exposures to environmental chemicals from biomarkers: challenges and opportunities. J. Expo. Sci. Environ. Epidemiol. 2009, 19(2):149-171.
31. Ginsberg G., Smolenski S., Neafsey P., Hattis D., Walker K., Guyton K.Z., Johns D.O., Sonawane B. The influence of genetic polymorphisms on population variability in six xenobiotic-metabolizing enzymes. J. Toxicol. Environ. Health, Part B: Crit. Rev. 2009, 12(5):307-333.
32. Ginsberg G., Smolenski S., Hattis D., Guyton K.Z., Johns D.O., Sonawane B. Genetic polymorphism in glutathione transferases (GST): population distribution of GSTM1, T1, and P1 conjugating activity. J. Toxicol. Environ. Health, Part B: Crit. Rev. 2009, 12(5):389-439.
33. Ginsberg G., Neafsey P., Hattis D., Guyton K.Z., Johns D.O., Sonawane B. Genetic polymorphism in paraoxonase 1 (PON1): population distribution of PON1 activity. J. Toxicol. Environ. Health, Part B: Crit. Rev. 2009, 12(5):473-507.
34. Ghosh P., Banerjee M., Giri A.K., Ray K. Toxicogenomics of arsenic: classical ideas and recent advances. Mutat. Res. 2008, 659(3):293-301.
35. Gohlke J.M., Thomas R., Zhang Y., Rosenstein M.C., Davis A.P., Murphy C., Becker K.G., Mattingly C.J., Portier C.J. Genetic and environmental pathways to complex diseases. BMC Syst. Biol. 2009, 3:46.
36. Griffiths C., McGartland A., Miller M. A comparison of the monetized impact of IQ decrements from mercury emissions. Environ. Health Perspect. 2007, 115(6):841-847.
37. Groopman J.D., Kensler T.W. The light at the end of the tunnel for chemical-specific biomarkers: daylight or headlight?. Carcinogenesis 1999, 20:1-11.
38. Grosse S.D., Matte T.D., Schwartz J., Jackson R.J. Economic gains resulting from the reduction in children's exposure to lead in the United States. Environ. Health Perspect. 2002, 110(6):563-569.
39. Gwinn M., Guessous I., Khoury M.J. Invited commentary: genes, environment, and hybrid vigor. Am. J. Epidemiol. 2009, 170:703-707.
40. Hattis D., Baird S., Goble R. A straw man proposal for a quantitative definition of the RfD. Drug Chem. Toxicol. 2002, 25(4):403-436.
41. Hein D.W., Doll M.A., Fretland A.J., Leff M.A., Webb S.J., Xiao G.H., Devanaboyina U.-S., Nangju N.A., Feng Y. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Pre 2000, 9:29-42.
42. Hogan K., Marcus A., Smith R., White P. Integrated exposure uptake biokinetic model for lead in children: empirical comparisons with epidemiologic data. Environ. Health Perspect. 1998, 106(Suppl 6):1557-1567.
43. Ikediobi O.N., Shin J., Nussbaum R.L., Phillips K.A., UCSF Center for Translational and Policy Research on Personalized Medicine, Walsh J.M., Ladabaum U., Marshall D. Addressing the challenges of the clinical application of pharmacogenetic testing. Clin. Pharmacol. Ther. 2009, 86(1):28-31.
44. The International HapMap Consortium A second generation human haplotype map of over 3.1million SNPs. Nature 2007, 449:851-861.
45. Ioannidis J.P.A., Boffetta P., Little J., O'brien T.R., Ultterlinden A.G., Vineis P., Balding D.J., Chokkalingam A., Dolan S.M., Flanders S.D., Higgins J.P.T., McCarthy M.I., McDermott D.H., page G.P., Rebbeck T.R., Seminara D., Khoury M.J. Assessment of cumulative evidence on genetic associations: intermim guidelines. Int. J. Epidemiol. 2008, 37:120-132.
46. Jonsson F., Johanson G. A Bayesian analysis of the influence of GSTT1 polymorphism on the cancer risk estimate for dichloromethane. Toxicol. Appl. Pharmacol. 2001, 174(2):99-112.
47. Jusko T.A., Henderson C.R., Lanphear B.P., Cory-Slechta D.A., Parsons P.J., Canfield R.L. Blood lead concentrations <10 microg/dL and child intelligence at 6years of age. Environ. Health Perspect. 2008 Feb, 116(2):243-248.
48. Kavlock R.J., Ankley G., Blancato J., Breen M., Conolly R., Dix D., Houck K., Hubal E., Judson R., Rabinowitz J., Richard A., Setzer R.W., Shah I., Villeneuve D., Weber E. Computational toxicology - a state of the science mini review. Toxicol. Sci. 2008, 103(1):14-27.
49. Kavlock R.J., Austin C.P., Tice R.R. Toxicity testing in the 21st century: implications for human health risk assessment. Risk Anal. 2009, 29(4):485-487. discussion 492-7.
50. Khoury M.J., Davis R., Swinn M., Lindegren M.L., Yoon P. Do we need genomic research for the prevention of common diseases with environmental causes?. Am. J. Epidemiol. 2005, 161:799-805.
51. Khoury M.J., Feero W.G., Reyes M., Citrin T., Freedman A., Leonard D. The genomic applications in practice and prevention network. Genet. Med. 2009, 11:488-494. the GAPPNet Planning Group.
52. Khoury M.J., Bertram L., Boffetta P., Butterworth A.S., Chanock S.J., Dolan S.M., Fortier I., Garcia-Closas M., Gwinn M., et al. Genomie-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am. J. Epidemiol. 2009, 170:269-279.
53. Khoury M.J., Wacholder S. Invited commentary: from genome-wide association studies to environment-wide interaction studies - challenges and opportunities. Am. J. Epidemiol. 2009, 169:227-230.
54. Lin B.K., Clyne M., Walsh M., Gomez O., Yu W., Gwinn M., Khoury M.J. Tracking the epidemiology of human genes in the literature: the HuGE Published Literature database. Am. J. Epidemiol. 2006, 164(1):1-4.
55. Lobenhofer E.K., Cui X., Bennett L., Cable P.L., Merrick B.A., Churchill G.A., Afshari C.A. Exploration of low-dose estrogen effects: identification of No Observed Transcriptional Effect Level (NOTEL). Toxicol. Pathol. 2004, 32(4):482-492.
56. Lund E., Dumeaux V. Systems epidemiology in cancer. Cancer Epidemiol. Biomarkers Prev. 2008, 17:2954-2957.
57. Makris, S., Euling, S.Y., Gray Jr., L.E., Benson, R., Foster, P., 2010-this issue. Dibutyl phthalate case study on the use of genomic data in risk assessment: I. Evaluation of the toxicity dataset. Toxicology and Applied Pharmacology Toxicogenomics in Risk Assessment Special Issue. Volume, Issue, Page Numbers TBD.
58. Miller M.D., Crofton K.M., Rice D.C., Zoeller R.T. Thyroid-disrupting chemicals: interpreting upstream biomarkers of adverse outcomes. Environ. Health Perspect. 2009, 117(7):1033-1041.
59. Myers J.P., vom Saal F.S., Akingbemi B.T., Arizono K., Belcher S., Colborn T., Chahoud I., Crain D.A., Farabollini F., Guillette L.J., Hassold T., Ho S.M., Hunt P.A., Iguchi T., Jobling S., Kanno J., Laufer H., Marcus M., McLachlan J.A., Nadal A., Oehlmann J., Olea N., Palanza P., Parmigiani S., Rubin B.S., Schoenfelder G., Sonnenschein C., Soto A.M., Talsness C.E., Taylor J.A., Vandenberg L.N., Vandenbergh J.G., Vogel S., Watson C.S., Welshons W.V., Zoeller R.T. Why public health agencies cannot depend on good laboratory practices as a criterion for selecting data: the case of bisphenol A. Environ. Health Perspect. Mar 2009, 117(3):309-315.
60. Mohrenweiser H.W. Genetic variation and exposure related risk estimation: will toxicology enter a new era? DNA repair and cancer as a paradigm. Toxicol. Pathol. 2004, 32(Suppl 1):136-145.
61. Naciff J.M., Jump M.L., Torontali S.M., et al. Gene expression profile induced by 17alpha-ethynyl estradiol, bisphenol A, and genistein in the developing female reproductive system of the rat. Toxicol. Sci. 2002, 68(1):184-199.
62. Naciff J.M., Overmann G.J., Torontali S.M., et al. Gene expression profile induced by 17 alpha-ethynyl estradiol in the prepubertal female reproductive system of the rat. Toxicol. Sci. 2003, 72(2):314-330.
63. Naciff J.M., Hess K.A., Overmann G.J., et al. Gene expression changes induced in the testis by transplacental exposure to high and low doses of 17α-ethynyl estradiol, genistein, or bisphenol A. Toxicol. Sci. 2005, 86(2):396-416.
64. Naciff J.M., Richardson B.D., Oliver K.G., Jump M.L., Torontali S.M., Juhlin K.D., Carr G.J., Paine J.R., Tiesman J.P., Daston G.P. Design of a microsphere-based high-throughput gene expression assay to determine estrogenic potential. Environ. Health Perspect. 2005, 113(9):1164-1171.
65. Naciff J.M., Khambatta Z.S., Thomason R.G., Carr G.J., Tiesman J.P., Singleton D.W., Khan S.A., Daston G.P. The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol. Sci. 2009, 107(1):40-55.
66. Nagel S.C., vom Saal F.S., Thayer K.A., Dhar M.G., Boechler M., Welshons W.V. Relative binding affinity-serum modified access (RBA-SMA) assay predicts the relative in vivo bioactivity of the xenoestrogens bisphenol A and octylphenol. Environ. Health Perspect. 1997, 105(1):70-76.
67. Dictionary of Cancer Terms 2010, NCI (National Cancer Institute), url: http://www.cancer.gov/dictionary/ (accessed March 16, 2010).
68. Applications of Toxicogenomic Technologies to Predictive Toxicology and Risk Assessment 2007, NRC (National Research Council), National Academy Press, Washington, DC.
69. Toxicity Testing in the 21st Century 2007, NRC (National Research Council), National Academy Press, Washington, DC.
70. Phthalates and Cumulative Risk Assessment - The Tasks Ahead 2008, NRC (National Research Council), National Academy Press, Washington, DC.
71. Science and Decisions 2009, NRC (National Research Council), National Academy Press, Washington, DC.
72. Neafsey P., Ginsberg G., Hattis D., Johns D.O., Guyton K.Z., Sonawane B. Genetic polymorphism in CYP2E1: population distribution of CYP2E1 activity. J. Toxicol. Environ. Health, Part B: Crit. Rev. 2009, 12(5):362-388.
73. Neafsey P., Ginsberg G., Hattis D., Sonawane B. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): population distribution of CYP2D6 activity. J. Toxicol. Environ. Health, Part B: Crit. Rev. 2009, 12(5):334-361.
74. Nuwaysir E.F., Bittner M., Trent J., Barrett J.C., Afshari C.A. Microarrays and toxicology: the advent of toxicogenomics. Mol. Carcinog. 1999, 24(3):153-159.
75. Ovacik, A.M., Ierapetritou, M.G., Sen, B., Gaido, K., Androulakis, I.P., 2010-this issue. A pathway activity method applied to microarray studies of the testis following in utero exposure to dibutyl phthalate (DBP). Toxicology and Applied Pharmacology Toxicogenomics in Risk Assessment Special Issue. Volume, Issue, Page Numbers TBD.
76. Péry A.R., Bois F.Y. Stochasticity in physiologically based kinetics models: implications for cancer risk assessment. Risk Anal. 2009, 29(8):1182-1191.
77. Pesch B., Brüning T., Frentzel-Beyme R., Johnen G., Harth V., Hoffmann W., Ko Y., Ranft U., Traugott U.G., Thier R., Taeger D., Bolt H.M. Challenges to environmental toxicology and epidemiology: where do we stand and which way do we go?. Toxicol. Lett. 2004, 151(1):255-266.
78. Quackenbush J. Extracting biology from high-dimensional biological data. J. Exp. Biol. 2007, 210(Pt 9):1507-1517.
79. Sen B., Wang A., Hester S.D., Robertson J.L., Wolf D.C. Gene expression profiling of responses to dimethylarsinic acid in female F344 rat urothelium. Toxicology 2005, 215(3):214-226. Erratum in: Toxicology. 2006. 220(2-3):240-1.
80. Slob W., Pieters M.N. A probabilistic approach for deriving acceptable human intake limits and human health risks from toxicological studies: general framework. Risk Anal. 1998, 18:787-798.
81. Snyder R.D., Green J.W. A review of the genotoxicity of marketed pharmaceuticals. Mutat. Res. 2001, 488(2):151-169.
82. Subramaniam R.P., Crump K.S., Van Landingham C., White P., Chen C., Schlosser P.M. Uncertainties in the CIIT model for formaldehyde-induced carcinogenicity in the rat: a limited sensitivity analysis-I. Risk Anal. 2007, 27(5):1237-1254.
83. Subramaniam R.P., Chen C., Crump K.S., Devoney D., Fox J.F., Portier C.J., Schlosser P.M., Thompson C.M., White P. Uncertainties in biologically-based modeling of formaldehyde-induced respiratory cancer risk: identification of key issues. Risk Anal. 2008, 28(4):907-923.
84. Tan Y.M., Liao K.H., Clewell H.J. Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling. J. Expo. Sci. Environ. Epidemiol. 2007, 17(7):591-603.
85. Thomas R.S., Allen B.C., Nong A., et al. A method to integrate benchmark dose estimates with genomic data to assess the functional effects of chemical exposure. Toxicol. Sci. 2007, 98(1):240-248.
86. Thomas R.S., O'Connell T.M., Pluta L., Wolfinger R.D., Yang L., Page T.J. A comparison of transcriptomic and metabonomic technologies for identifying biomarkers predictive of two-year rodent cancer bioassays. Toxicol. Sci. 2007, 96(1):40-46.
87. Thomas R.S., Pluta L., Yang L., Halsey T.A. Application of genomic biomarkers to predict increased lung tumor incidence in 2-year rodent cancer bioassays. Toxicol. Sci. 2007, 97(1):55-64. May 2007.
88. Thomas R.S., Bao W., Chu T.M., Bessarabova M., Nikolskaya T., Nikolsky Y., Andersen M.E., Wolfinger R.D. Use of short-term transcriptional profiles to assess the long-term cancer-related safety of environmental and industrial chemicals. Toxicol. Sci. 2009, 112(2):311-321.
89. Thomas R., Gohlke J.M., Stopper G.F., Parham F.M., Portier C.J. Choosing the right path: enhancement of biologically relevant sets of genes or proteins using pathway structure. Genome Biol. 2009, 10(4):R44.
90. Thompson C.M., Sonawane B., Barton H.A., DeWoskin R.S., Lipscomb J.C., Schlosser P., Chiu W.A., Krishnan K. Approaches for applications of physiologically based pharmacokinetic models in risk assessment. J. Toxicol. Environ. Health B Crit. Rev. 2008, 11(7):519-547.
91. Trasande L., Landrigan P.J., Schechter C. Public health and economic consequences of methyl mercury toxicity to the developing brain. Environ. Health Perspect. 2005, 113(5):590-596.
92. 3/4/day. Fed. Regist. 1992, 57(109):24152-24173.
93. Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry 1994, U.S. EPA, EPA/600/8-90/066F.
94. The Benefits and Costs of the Clean Air Act, 1970-1990 1997, U.S. EPA, U.S. Environmental Protection Agency, Washington, DC.
95. A Review of the Reference Dose and Reference Concentration Processes 2002, U.S. EPA, EPA/630/P-02/2002F.
96. Science Policy Council Interim Policy on Genomics 2002, U.S. EPA, Available online at http://www.epa.gov/spc/pdfs/genomics.pdf.
97. Guidelines for Carcinogen Risk Assessment 2005, U.S. EPA (Environmental Protection Agency), Risk Assessment Forum, Washington, DC, EPA/630/P-03/001B. Available online at http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=116283.
98. Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens 2005, U.S. EPA (Environmental Protection Agency), Risk Assessment Forum, Washington, DC, EPA/630/R-03/003F. Available online at http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=160003.
99. Approaches for the Application of Physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment (Final Report) 2006, U.S. EPA, US Environmental Protection Agency EPA/600/R-05/043A, Washington, D.C.
100. The First International Workshop on Virtual Tissues: v-Tissues 2009 2009, U.S. EPA, http://www.epa.gov/ncct/virtual_tissues/.
101. Vineis P., Kriebel D. Causal models in epidemiology: past inheritance and genetic future. Environ. Health 2006, 5:21. 10.1186/1476-069X-5-21.
102. Vineis P., Perera F. Molecular epidemiology and biomarkers in etiologic cancer research: the new in light of the old. Cancer Epidemiol. Biomarkers Prev. 2007, 16:1954-1965.
103. Vineis P., Brennan P., Canzlan F., Ioannidis J.P.A., Mutullo G., Ritchie M., Stromberg U., Taioli E., Thompson J. Expectation and challenges stemming from genome-wide association studies. Mutagenesis 2008, 23:439-444.
104. vom Saal F.S., Timms B.G., Montano M.M., Palanza P., Thayer K.A., Nagel S.C., Dhar M.D., Ganjam V.K., Parmigiani S., Welshons W.V. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc. Natl. Acad. Sci. USA 1997, 94(5):2056-2061. Mar 4 1997.
105. Walker K., Ginsberg G., Hattis D., Johns D.O., Guyton K.Z., Sonawane B. Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity. J. Toxicol. Environ. Health, Part B: Crit. Rev. 2009, 12(5):440-472.
106. Weiss S.T., McLeod H.L., Flockhart D.A., Dolan M.E., Benowitz N.L., Johnson J.A., Ratain M.J., Giacomini K.M. Creating and evaluating genetic tests predictive of drug response. Nat. Rev. Drug Discov. 2008, 7(7):568-574.
107. White, L.D., Euling, S.Y., Gaido, K.W., Hester, S., Keshava, C., Keshava, N., Kim, A.S., Ovacik, A.M., Sen, S., Wilson, V.S., 2010-this issue. Dibutyl phthalate case study on the use of genomic data in risk assessment: II. Evaluation of the toxicogenomic dataset. Toxicology and Applied Pharmacology Toxicogenomics in Risk Assessment Special Issue. Volume, Issue, Page Numbers TBD.
108. Biomarkers and Risk Assessment: Concepts and Principles (Environmental Health Criteria 155) 1993, WHO (World Health Organization).
109. Guidance Document for the Use of Data in Development of Chemical-specific Adjustment Factors (CSAFs) for Interspecies Differences and Human Variability in Dose/concentration Response Assessment 2001, WHO, World Health Organization, International Programme on Chemical Safety, Geneva.
110. Woodruff T.J., Zeise L., Axelrad D.A., Guyton K.Z., Janssen S., Miller M., Miller G.G., Schwartz J.M., Alexeeff G., Anderson H., Birnbaum L., Bois F., Cogliano V.J., Crofton K., Euling S.Y., Foster P.M., Germolec D.R., Gray E., Hattis D.B., Kyle A.D., Luebke R.W., Luster M.I., Portier C., Rice D.C., Solomon G., Vandenberg J., Zoeller R.T. Meeting report: moving upstream-evaluating adverse upstream end points for improved risk assessment and decision-making. Environ. Health Perspect. 2008, 116(11):1568-1575.
111. Yang L., Allen B.C., Thomas R.S. BMDExpress: a software tool for the benchmark dose analyses of genomic data. BMC Genomics 2007, 8:387.
112. Yu X., Griffith W.C., Hanspers K., Dillman J.F., Ong H., Vredevoogd M.A., Faustman E.M. A system-based approach to interpret dose- and time-dependent microarray data: quantitative integration of gene ontology analysis for risk assessment. Toxicol. Sci 2006, 92(2):560-577.